Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and gastrointestinal endoscopies, according to new ...

Results from the trial included a 140% average increase in GLP-1 levels in the body leading to an average weight loss of 9 pounds in 8 weeks and up to 25 pounds in 12 weeks in participants.

LifeVantage (LFVN) announced results from a human clinical trial performed on the new MindBody GLP-1 System. Results from the trial included a 140% average increase in GLP-1 levels in the body ...

New Resource Offers Tailored Smoothie Menu for Individuals Incorporating GLP-1 Weight Loss Medications into Their Health & Wellness Routines DALLAS, Oct. 29, 2024 /PRNewswire/ -- Smoothie King ...

News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to their astronomical pricing, drug shortages, compounding disputes ...

PHILADELPHIA — The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with a significant decrease in the risk for early-onset colorectal cancer (EO-CRC) in patients with ...

Some 12% — or about 1 in 8 — people living in the U.S. have tried a GLP-1 drug, according to a survey by the Kaiser Family Foundation. And with that drug comes many dietary changes that need ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity. HealthDay News — From 2010 to 2023, there was an ...

Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing elective surgery and gastrointestinal endoscopies, according to new ...

DALLAS —Smoothie King has created a GLP-1 support menu for consumers using the prescription weight-loss drugs. The Dallas-based quick-service restaurant chain said the menu will be available ...

Evoke Pharma (NASDAQ:EVOK) shares rocketed 90% early Monday on positive data for its nasal drug Gimoti in the treatment of stomach paralysis in diabetic patients using GLP-1 drugs. The study ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Key ...